Skip to main content
SpringerLink
Log in

Bone

Romosozumab — getting there but not quite yet

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

In a recent study by Cosman and colleagues, romosozumab — a humanized monoclonal antibody targeting sclerostin — is shown to reduce the risk of vertebral and clinical fractures at 12 months compared with placebo. However, the low fracture risk of study participants necessitates the completion of an on-going clinical trial before romosozumab can be fully adopted into clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baron, R. & Kneissel, M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179–192 (2013).

    Article  CAS  Google Scholar 

  2. Appelman-Dijkstra, N. M. & Papapoulos, S. E. Sclerostin inhibition in the management of osteoporosis. Calcif. Tissue Int. 98, 370–380 (2016).

    Article  CAS  Google Scholar 

  3. Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).

    Article  CAS  Google Scholar 

  4. McClung, M. R. et al. Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density. J. Bone Miner. Res. 29 (Suppl. 1), S53 (2014).

    Google Scholar 

  5. Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809–1822 (2007).

    Article  CAS  Google Scholar 

  6. Bone, H. G. et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial. Osteoporos. Int. 26, 699–712 (2015).

    Article  CAS  Google Scholar 

  7. Harris, S. T. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282, 1344–1352 (1999).

    Article  CAS  Google Scholar 

  8. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).

    Article  CAS  Google Scholar 

  9. Kolata, G. Fearing rare side effects, millions take their chances with osteoporosis. The New York Times http://www.nytimes.com/2016/06/02/health/osteoporosis-drugs-bones.html (2016).

  10. Khosla, S. & Shane, E. A crisis in the treatment of osteoporosis. J. Bone Miner. Res. 31, 1485–1487 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Endocrinology, Center for Bone Quality, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, Netherlands

    Socrates E. Papapoulos

Authors
  1. Socrates E. Papapoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Socrates E. Papapoulos.

Ethics declarations

Competing interests

S.E.P. has received consulting and speaking fees from Amgen and UCB, and consulting fees from Mereo Biopharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Papapoulos, S. Romosozumab — getting there but not quite yet. Nat Rev Endocrinol 12, 691–692 (2016). https://doi.org/10.1038/nrendo.2016.179

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2016.179

  • Springer Nature Limited

This article is cited by

Search

Navigation